1027493-29-3

Upstream product

• 1027493-28-2 2-[3-(4-chloro-benzoyl)-4-methyl-thiophen-2-yl]-isoindole-1,3-dione 

Downstream Products

• 1027493-30-6 2-[5-bromo-4-bromomethyl-3-(4-chloro-benzoyl)-thiophen-2-yl]-isoindole-1,3-dione 
• 1027493-41-9 2-[3-(4-chlorobenzoyl)-4-methyl-5-phenylthiophen-2-yl]isoindoline-1,3-dione 
• 1394868-08-6 2-[3-(4-chlorobenzoyl)-5-(4-chlorophenyl)-4-methylthiophen-2-yl]isoindoline-1,3-dione 
• 1394868-07-5 2-[3-(4-chlorobenzoyl)-5-(4-fluorophenyl)-4-methylthiophen-2-yl]isoindoline-1,3-dione 
• 1394868-05-3 2-{3-(4-chlorobenzoyl)-5-(4-chlorophenyl)-4-[(4-(2-(trifluoromethyl)phenyl)piperazin-1-yl)methyl]thiophen-2-yl}isoindoline-1,3-dione 
• 1394868-04-2 2-{3-(4-chlorobenzoyl)-5-(4-chlorophenyl)-4-[(4-(4-chloro-3-(trifluoromethyl)phenyl)piperazin-1-yl)methyl]thiophen-2-yl}isoindoline-1,3-dione 
• 1394868-03-1 2-{3-(4-chlorobenzoyl)-5-(4-chlorophenyl)-4-[(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)methyl]-thiophen-2-yl}isoindoline-1,3-dione 
• 1394868-02-0 2-{3-(4-chlorobenzoyl)-5-(4-chlorophenyl)-4-[(4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)methyl]thiophen-2-yl}isoindoline-1,3-dione 
• 1394868-01-9 2-{3-(4-chlorobenzoyl)-4-[(4-(3,4-dichlorophenyl)piperazin-1-yl)methyl]-5-(4-chlorophenyl)thiophen-2-yl}isoindoline-1,3-dione 
• 1394868-00-8 2-{3-(4-chlorobenzoyl)-4-[(4-(4-chlorophenyl)piperazin-1-yl)methyl]-5-(4-chlorophenyl)thiophen-2-yl}isoindoline-1,3-dione 
• 1394867-99-2 2-{3-(4-chlorobenzoyl)-4-[(4-(4-fluorophenyl)piperazin-1-yl)methyl]-5-(4-chlorophenyl)thiophen-2-yl}isoindoline-1,3-dione 
• 1394867-98-1 2-[(4-(4-benzylpiperazin-1-yl)methyl)-3-(4-chlorobenzoyl)-5-(4-chlorophenyl)thiophen-2-yl]isoindoline-1,3-dione 
• 1394867-97-0 2-[5-(4-chlorophenyl)-3-(4-chlorobenzoyl)-4-[(4-phenylpiperazin-1-yl)methyl]thiophen-2-yl]isoindoline-1,3-dione 
• 1394867-96-9 2-{3-(4-chlorobenzoyl)-4-[(4-(4-fluorophenyl)piperazin-1-yl)methyl]-5-(4-fluorophenyl)thiophen-2-yl}isoindoline-1,3-dione 

Relevant academic research and scientific papers

ALLOSTERIC ENHANCERS OF THE A1 ADENOSINE RECEPTOR

The present invention provides compounds of formula (I) wherein W, R1, R5 and R6 have a meaning as defined herein in the specification. The compounds of formula (I) are allosteric enhancers of the A1 adenosine receptor and, thus, may be employed for the treatment of conditions mediated by the A1 adenosine receptor. Accordingly, the compounds of formula (I) may be employed for treatment of pain, in particular, chronic pain such as neuropathic pain, and inflammatory pain, cardiac disease or disorder such as cardiac disarrhythmias, e.g., peroxysmal supraventricular tachycardia, angina, myocardial infarction and stroke, neurological disease or injury, sleep disorders, epilepsy and depression.

Synthesis and biological evaluation of 2-amino-3-(4-chlorobenzoyl)-4-[N- (substituted) piperazin-1-yl]thiophenes as potent allosteric enhancers of the A1 adenosine receptor

The synthesis and evaluation of a series of 2-amino-3-(4-chlorobenzoyl)-4- [4-(alkyl/aryl)piperazin-yl]thiophene derivatives as allosteric enhancers of the A1-adenosine receptor are described. The nature of substituents on the phenyl ring tethered to the piperazine seem to exert a fundamental influence on the allosteric enhancer activity, with the 4-chlorophenyl 8f and 4-trifluoromethyl 8j derivatives being the most active compounds in binding (saturation and displacement experiments) and functional cAMP studies.

ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR

The present invention provides compounds of formula (I) wherein R1, R2, R3, R4 and Q have a meaning as defined herein in the specification. The compounds of formula (I) are allosteric modulators of the A1 adenosine receptor and, thus, may be employed for the treatment of conditions mediated by the A1 adenosine receptor. Accordingly, the compounds of formula (I) may be employed for treatment of pain, in particular, chronic pain such as neuropathic pain; cardiac disease or disorder such as cardiac disarrhythmias, e.g., peroxysmal supraventricular tachycardia, angina, myocardial infarction and stroke; neurological disease or injury; sleep disorder; epilepsy; and depression.